Please sign in to follow a disease.
Armata Pharmaceuticals, Inc.
Clinical trials sponsored by Armata Pharmaceuticals, Inc., explained in plain language.
A clinical-stage biotech developing bacteriophage therapies for antibiotic-resistant infections.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug shows promise against staph blood infections
Disease control CompletedThis study tested a new medicine called AP-SA02, given through a vein, along with standard antibiotics for adults with a Staph blood infection. The main goal was to check if the combination is safe and tolerable. Researchers also looked at whether it helped clear the infection fa…
Phase 1/2 • Sponsor: Armata Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Virus cocktail inhaled to fight Drug-Resistant lung infection
Disease control CompletedThis study tested an inhaled mixture of bacteria-killing viruses (phages) in 48 adults with bronchiectasis and chronic Pseudomonas lung infections. Participants received either the phage therapy or a placebo by inhalation. The goal was to see if the phages could safely reduce the…
Phase 2 • Sponsor: Armata Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC